Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 11/20 | 0.76 |
| ▸ | GPR174 | Q9BXC1 | 9/20 | 0.76 |
| ▸ | GPR34 | Q9UPC5 | 6/20 | 0.76 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.73 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.73 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.73 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.73 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.73 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.73 |
| ▸ | CES2 | O00748 | 1/20 | 0.73 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.73 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25354353 | 1.00 | P2RY10 (0.76) | P2RY10GPR174GPR34LPAR1ENPP2 | |
| SCHEMBL31442523 | 1.00 | P2RY10 (0.76) | P2RY10GPR174GPR34LPAR1ENPP2 | |
| SCHEMBL274999 | 1.00 | P2RY10 (0.76) | P2RY10GPR174GPR34LPAR1ENPP2 | |
| SCHEMBL14924218 | 1.00 | P2RY10 (0.76) | P2RY10GPR174GPR34LPAR1ENPP2 | |
| SCHEMBL31442307 | 1.00 | P2RY10 (0.76) | P2RY10GPR174GPR34LPAR1ENPP2 | |
| SCHEMBL30913715 | 0.98 | LPAR1 (0.73) | P2RY10GPR174GPR34LPAR1ENPP2 | |
| SCHEMBL32666125 | 0.97 | P2RY10 (0.71) | P2RY10GPR174GPR34LPAR1ENPP2 | |
| SCHEMBL275621 | 0.97 | P2RY10 (0.71) | P2RY10GPR174GPR34LPAR1ENPP2 | |
| SCHEMBL17929051 | 0.97 | P2RY10 (0.71) | P2RY10GPR174GPR34LPAR1ENPP2 | |
| SCHEMBL275624 | 0.94 | LPAR1 (0.67) | P2RY10GPR174GPR34LPAR1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637812-A1 | HEPATITIS B COMPOSITIONS | GlaxoSmithKline Biologicals S.A. (BE) | 2025-10-29 | — | — | EP | disclosed |
| EP-4539876-A2 | RECOMBINANT RNA MOLECULES COMPRISING UNTRANSLATED REGIONS OR SEGMENTS ENCODING SPIKE PROTEIN FROM THE OMICRON STRAIN OF SEVERE ACUTE RESPIRATORY CORONAVIRUS-2 | GlaxoSmithKline Biologicals S.A. (BE) | 2025-04-23 | — | — | EP | disclosed |
| US-20250099576-A1 | Recombinant RNA Molecules Comprising Untranslated Regions or Segments Encoding Spike Protein from the Omicron Strain of Severe Acute Respiratory Coronavirus-2 | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2025-03-27 | — | — | US | disclosed |
| WO-2024133160-A1 | HEPATITIS B COMPOSITIONS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-06-27 | — | — | WO | disclosed |
| US-20240189417-A1 | SUBSTITUTION OF NUCLEOTIDE BASES IN SELF-AMPLIFYING MESSENGER RIBONUCLEIC ACIDS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-06-13 | — | — | US | disclosed |
| WO-2023242817-A2 | RECOMBINANT RNA MOLECULES COMPRISING UNTRANSLATED REGIONS OR SEGMENTS ENCODING SPIKE PROTEIN FROM THE OMICRON STRAIN OF SEVERE ACUTE RESPIRATORY CORONAVIRUS-2 | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-12-21 | — | — | WO | disclosed |
| US-20230305011-A1 | LIPIDOMICS-BASED IDENTIFICATION OF PATIENTS FOR TREATMENT OF CANCER USING COMPUTED NORMALIZED RATIOS OF CIRCULATING PHOSPHOLIPIDS | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2023-09-28 | — | — | US | disclosed |
| US-11703508-B2 | Lipidomics-based identification of patients bearing ovarian tumors | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2023-07-18 | — | — | US | disclosed |
| WO-2023031855-A1 | SUBSTITUTION OF NUCLEOTIDE BASES IN SELF-AMPLIFYING MESSENGER RIBONUCLEIC ACIDS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-03-09 | — | — | WO | disclosed |
| US-20200319190-A1 | LIPIDOMICS-BASED IDENTIFICATION OF PATIENTS FOR TREATMENT OF CANCER USING COMPUTED NORMALIZED RATIOS OF CIRCULATING PHOSPHOLIPIDS | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099576-A1 | Recombinant RNA Molecules Comprising Untranslated Regions or Segments Encoding Spike Protein from the Omicron Strain of Severe Acute Respiratory Coronavirus-2 | RNGTT, RBM25, TMPRSS2 | P2RY10 3576/4885GPR174 2621/4885GPR34 3580/4885 |
| US-20240189417-A1 | SUBSTITUTION OF NUCLEOTIDE BASES IN SELF-AMPLIFYING MESSENGER RIBONUCLEIC ACIDS | NSUN2, NSUN3, RNMT | P2RY10 2143/4885GPR174 3092/4885GPR34 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.